Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | KEAP1 | Q14145 | 5/20 | 0.56 |
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22887508 | 1.00 | KDM4E (0.60) | KDM4ETSHRTP53KEAP1NFE2L2 | |
| SCHEMBL22887464 | 0.92 | LTA4H (0.56) | KDM4ETSHRTP53KEAP1NFE2L2 | |
| SCHEMBL26975791 | 0.92 | LTA4H (0.56) | KDM4ETSHRTP53KEAP1NFE2L2 | |
| SCHEMBL4698008 | 0.90 | KDM4E (0.70) | KDM4ETSHRTP53KEAP1NFE2L2 | |
| SCHEMBL22887473 | 0.88 | KEAP1 (0.58) | KDM4ETSHRTP53KEAP1NFE2L2 | |
| SCHEMBL22887366 | 0.86 | KEAP1 (0.54) | KDM4ETSHRTP53KEAP1NFE2L2 | |
| SCHEMBL29417693 | 0.82 | KDM4E (0.62) | KDM4ETSHRTP53MAPTALDH1A1 | |
| SCHEMBL210600 | 0.82 | KDM4E (0.62) | KDM4ETSHRTP53MAPTALDH1A1 | |
| SCHEMBL10021702 | 0.81 | KEAP1 (0.57) | KDM4ETSHRTP53KEAP1NFE2L2 | |
| SCHEMBL29496407 | 0.81 | KEAP1 (0.57) | KDM4EKEAP1NFE2L2ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858889-B2 | Compound for modulating DDAH and ADMA levels, as well as methods of using thereof to treat disease | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858889-B2 | Compound for modulating DDAH and ADMA levels, as well as methods of using thereof to treat disease | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-20220144795-A1 | COMPOUND FOR MODULATING DDAH AND ADMA LEVELS, AS WELL AS METHODS OF USING THEREOF TO TREAT DISEASE | UNIV INDIANA TRUSTEES (US) | 2022-05-12 | — | — | US | disclosed |
| US-20210009498-A1 | COMPOUND FOR MODULATING DDAH AND ADMA LEVELS, AS WELL AS METHODS OF USING THEREOF TO TREAT DISEASE | THE TRUSTEES OF INDIANA UNIVERSITY | 2021-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11858889-B2 | Compound for modulating DDAH and ADMA levels, as well as methods of using thereof to treat disease | ADM2, DDAH1, BHMT | KDM4E 3545/4885TSHR 3744/4885TP53 2885/4885 |
| US-20220144795-A1 | COMPOUND FOR MODULATING DDAH AND ADMA LEVELS, AS WELL AS METHODS OF USING THEREOF TO TREAT DISEASE | ADM2, DDAH1, BHMT | KDM4E 3545/4885TSHR 3744/4885TP53 2885/4885 |
| US-20210009498-A1 | COMPOUND FOR MODULATING DDAH AND ADMA LEVELS, AS WELL AS METHODS OF USING THEREOF TO TREAT DISEASE | ADM2, DDAH1, BHMT | KDM4E 3545/4885TSHR 3744/4885TP53 2885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.